

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

203565Orig1s000

STATISTICAL REVIEW(S)



U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Translational Sciences
Office of Biostatistics

STATISTICAL REVIEW AND EVALUATION

CLINICAL STUDIES

NDA/BLA Serial Number: NDA 203565/0

Drug Name: Ferric Carboxymaltose

Indication(s): Iron Deficiency Anemia

Applicant: Luitpold Pharmaceuticals, Inc.

Date(s): Stamp Date: 10/3/2011
PUDFA Date: August 3, 2012

Review Priority: Standard

Biometrics Division: Division of Biometrics V

Statistical Reviewer: Kyung Yul Lee, Ph.D., Statistical Reviewer

Concurring Reviewers: Mark Rothmann, Ph.D., Lead Mathematical Statistician
Tomas Gwise, Ph.D., Division Deputy Director

Medical Division: Division of Hematology Products

Clinical Team: Dr. Min Lu, Clinical Reviewer
Dr. Kathy Robie Suh, Clinical Team Leader

Project Manager: Ms. Baird

Keywords:

Iron deficiency anemia, impaired renal function, hemoglobin, noninferiority test, ANCOVA,

Table of Contents

LIST OF TABLES.....	3
LIST OF FIGURES.....	4
1. EXECUTIVE SUMMARY	5
2. INTRODUCTION	6
2.1 OVERVIEW.....	6
2.2 DATA SOURCES	8
3. STATISTICAL EVALUATION	8
3.1 DATA AND ANALYSIS QUALITY	8
3.2 EVALUATION OF EFFICACY	8
3.2.1 <i>IVIT9030</i>	8
3.2.2 <i>IVIT9031</i>	17
3.3 EVALUATION OF SAFETY	29
4. FINDINGS IN SPECIAL/SUBGROUP POPULATIONS	32
4.1 GENDER, RACE, AGE, AND GEOGRAPHIC REGION	32
4.2 OTHER SPECIAL/SUBGROUP POPULATIONS	34
5. SUMMARY AND CONCLUSIONS	36
5.1 STATISTICAL ISSUES AND COLLECTIVE EVIDENCE	36
5.2 CONCLUSIONS AND RECOMMENDATIONS	37
SIGNATURES/DISTRIBUTION LIST.....	38

LIST OF TABLES

Table 1 : List of all studies included in analysis.....	7
Table 2 : Patient Disposition: Treated Population (Study 1VIT9030).....	10
Table 3 : Number of subjects in Treated and mITT Populations (Study 1VIT9030).....	12
Table 4 : Demographic Characteristics: Treated Population (Study 1VIT9030).....	12
Table 5 : Baseline Characteristics: Treated Population (Study 1VIT9030).....	13
Table 6 : Mean Change in Hemoglobin from Baseline to the Highest Value between Baseline and Day 56 (or time of intervention): mITT Population (Study 1VIT9030).....	14
Table 7 : Percent of Subjects With an Increase in Hemoglobin \geq 1.0 g/dL Anytime Between Baseline and Day 56 (or time of intervention): mITT population (Study 1VIT9030).....	16
Table 8 : Mean Change in Ferritin, TSAT, Serum Iron, TIBC, Unsaturated IBC from Baseline to the Highest Value between Baseline and Day 56 ((or time of intervention)): mITT Population (Study 1VIT9030).....	16
Table 9: Patient Disposition (Study 1VIT9031): Treated Population.....	20
Table 10: Demographic Characteristics (Study 1VIT9031): Treated Population.....	21
Table 11: Baseline Characteristics (Study 1VIT9031): Treated Population.....	22
Table 12: Mean Change in Hemoglobin from Baseline to the Highest Value between Baseline and Day 35 (or time of intervention) (mITT) (Cohort 1 in Study 1VIT9031).....	24
Table 13: Mean Change in Hemoglobin from Baseline to the Highest Value between Baseline and Day 35 (or time of intervention) (mITT) (Cohort 2 in Study 1VIT9031).....	24
Table 14: Proportion of Subjects Achieving a Hemoglobin $>$ 12.0 g/dL Anytime between Baseline and Day 35 (or time of intervention): mITT population (Study 1VIT9031).....	25
Table 15: Mean Change in Ferritin from Baseline to the Highest Value between Baseline and Day 35 (or time of intervention): mITT Population (Cohort 1 in Study 1VIT9031).....	25
Table 16: Proportion of Subjects with Hemoglobin $>$ 12.0 g/dL and an Increase in Ferritin.....	26
Table 17: Proportion of Subjects with a Clinically Meaningful Increase in Hemoglobin.....	27
Table 18: Mean Change in Hemoglobin and Other Iron Indices from Baseline to Day 35 (or time of intervention): mITT Population (Cohort 1 in Study 1VIT9031).....	28
Table 19: Mean Change in Hemoglobin and Other Iron Indices from Baseline to Day 35 (or time of intervention): mITT Population (Cohort 2 in Study 1VIT9031).....	28
Table 20: Primary Composite Safety Endpoint: Safety Population (Study 1VIT9030).....	30
Table 21: Summary Results for Primary Composite Safety Endpoint Analyses (Study 1VIT9030).....	30
Table 22: Cox Proportional Hazard Analyses Results for Primary Composite Safety Endpoint (Study 1VIT9030).....	31
Table 23: Primary Composite Safety Endpoint: Safety Population (Study 1VIT9031).....	32
Table 24: Study 1VIT9030 Subgroup Analyses for Mean Change in Hemoglobin from Baseline to the Highest Value between Baseline and Day 56 (or time of intervention): Age, Gender and Race: mITT Population.....	33
Table 25: Study 1VIT9031 Subgroup Analyses for Mean Change in Hemoglobin from Baseline to the Highest Value between Baseline and Day 35 (or time of intervention): Age, Gender and Race: mITT Population.....	34
Table 26 : Mean Change in Hemoglobin from Baseline to the Highest Value between Baseline and Day 56 ((or time of intervention)) by Baseline Hemoglobin: mITT Population (Study 1VIT9030).....	35

LIST OF FIGURES

Figure 1: Mean Hemoglobin Change from Baseline (Study 1VIT9030)	15
Figure 2: Mean Hemoglobin Change from Baseline (Study 1VIT9031)	29
Figure 3: Kaplan Meier Curves for the Primary Composite Safety Endpoint (Study 1VIT9030)	31

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.